Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Tomazic

Family Medicine Forest City, PA Doctor of Osteopathy

NPI 1912992751 CMS profile 41171

100 Dundaff St, Forest City, PA 18421

Open in the dashboard

General payments

$7,343

459 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Tomazic of Forest City, PA is reported in the CMS Open Payments database as having received $7,343 across 459 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,329 76
2024 General $1,304 72
2023 General $1,078 67
2022 General $757 42
2021 General $995 68
2020 General $675 46
2019 General $1,205 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Tomazic
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to David Tomazic were reported at $1,329. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year David Tomazic Family Medicine median Middle half National median
2019 $1,205 $150 $41–$543 $163
2020 $675 $120 $32–$415 $114
2021 $995 $137 $35–$551 $132
2022 $757 $137 $37–$512 $149
2023 $1,078 $149 $42–$545 $160
2024 $1,304 $156 $44–$560 $164
2025 $1,329 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,176 73 payments
  2. AstraZeneca Pharmaceuticals LP $866 52 payments
  3. Lilly USA, LLC $725 57 payments
  4. GlaxoSmithKline, LLC. $574 38 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $535 33 payments
  6. Pfizer Inc. $383 22 payments
  7. Otsuka America Pharmaceutical, Inc. $326 14 payments
  8. Amgen Inc. $216 14 payments
  9. Astellas Pharma US Inc $203 11 payments
  10. Janssen Pharmaceuticals, Inc $180 16 payments
  11. Other $2,160 129 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,284 455 payments
  2. Education $59 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $865 52 payments
  2. RYBELSUS $852 52 payments
  3. FARXIGA $567 33 payments
  4. JARDIANCE Diabetes $416 38 payments
  5. TRELEGY ELLIPTA $407 27 payments
  6. REXULTI $326 14 payments
  7. JARDIANCE Diabetes $295 17 payments
  8. Wegovy $205 14 payments
  9. ELIQUIS $188 10 payments
  10. INVOKANA $180 16 payments
  11. Other $5,827 367 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 240 drugs

Part D claims

30,196

Median for Family Practice: 1,826

Drug cost

$1,589,948

Median for Family Practice: $120,094

Branded share of claims

18.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 934 $309,476
Jardiance Empagliflozin Brand 202 $131,238
Oxycontin Oxycodone Hcl Brand 13 $102,639
Ozempic Semaglutide Brand 77 $72,744
Januvia Sitagliptin Phosphate Brand 213 $67,340
Myrbetriq Mirabegron Brand 212 $51,075
Roxicodone Oxycodone Hcl Brand 13 $46,932
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 54 $41,702
Xarelto Rivaroxaban Brand 75 $38,673
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 29 $31,232

The 10 drugs with the highest cost, of 240 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $107
  • Lundbeck LLC $40
$147 45 —
JARDIANCE
  • Lilly USA, LLC $85
  • Boehringer Ingelheim Pharmaceuticals, Inc. $56
$141 202 —
RYBELSUS
  • Novo Nordisk Inc $109
$109 15 —
Ozempic
  • Novo Nordisk Inc $107
$107 77 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

459 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record